Browsing by Author Sofia, MJ

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 9 of 9
TitleAuthor(s)Issue DateViews
 
A single dose of the GalNAc-siRNA, AB-729, results in prolonged reductions in HBsAg, HBcrAg, HBV DNA and HBV RNA in the absence of nucleos (t)ide analogue therapy in HBeAg negative subjects with chronic hepatitis B infection
Proceeding/Conference:Journal of Hepatology
Gane, ESevinsky, HYuen, RMFAnderson, MCloherty, GThi, EPWattamwar, TSofia, MJGray, KAntoniello, DEley, TPicchio, GSims, K
2021
9
 
Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 in chronic hepatitis B patients correlates with suppression of all HBsAg isoforms and HBV RNA
Proceeding/Conference:Journal of Hepatology
Thi, EPYuen, RMFGane, ESevinsky, HSims, KAnderson, MLam, AMSofia, MJCloherty, GPicchio, G
2021
10
 
Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 is associated with increased cytokine signatures in HBV DNA+ chronic hepatitis B patients. Poster Presentation (SAT396)
Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology
Ganchua, SParatala, BIott, CYuen, RMFGane, EJEley, TSims, KGray, KAntoniello, DLam, AMSofia, MJPicchio, GThi, EP
2022
 
Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T cell activation markers
Proceeding/Conference:Journal of Hepatology
Paratala, BPark, J-JGanchua, SCGane, EYuen, RMFLee, ACHMoore, CLam, AMSevinsky, HSims, KAntoniello, DSofia, MJPicchio, GThi, EP
2021
10
 
Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells. Poster Presentation (SAT397)
Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology
Ganchua, SCParatala, BIott, CGane, EJYuen, RMFEley, TSims, KGray, KAntoniello, DLam, AMSofia, MJPicchio, GThi, EP
2022
1
 
Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression
Proceeding/Conference:Journal of Hepatology
Yuen, RMFBerliba, ESukeepaisarnjaroen, WStrasser, STangkijvanich, PHolmes, JLeerapun, AJucov, AThi, EPWattamwar, TSofia, MJSevinsky, HGray, KAntoniello, DEley, TPicchio, GSims, KGane, E
2021
14
 
Safety and pharmacodynamics of the GALNAC-siRNA AB-729 in subjects with chronic hepatitis B infection
Proceeding/Conference:Hepatology
Yuen, RMFBerliba, EKim, YJHolmes, JALim, YSStrasser, SISchwabe, CJucov, ALee, ACHThi, EPHarasym, TPamulapati, GRWattamwar, PKunta, JSofia, MJSevinsky, HGray, KEley, TPicchio, GRSims, KGane, EJ
2020
19
 
Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects(HS) and subjects with chronic hepatitis B (CHB). Poster Presentation (SAT392)
Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology
Gane, EJJucov, AKolomiichuk, LEley, TBrown, JKing, YMedvedeva, EChernyakhovskyy, MMani, NCole, AGKultgen, SGPamulapati, RThi, EPHarasym, TODugyala, RChaudhari, SSofia, MJChild, MPicchio, GSims, KYuen, RMF
2022
 
Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the capsid inhibitor (CI) AB-506 in healthy subjects (HS) and chronic hepatitis B (CHB) subjects
Proceeding/Conference:Hepatology
Yuen, RMFBerliba, ESukeepaisarnjaroen, WAhn, SHTanwandee, TLim, Y-SKim, YJPoovorawan, KTangkijvanich, PChan, HLYEley, TBrown, JMoore, CLee, ACHKim, JThi, EPMani, NRijnbrand, RCole, ASofia, MJPicchio, GRSims, KGane, EJ
2019
48
Showing results 1 to 9 of 9